Charged Alpha Stock Encyclopedia

Devon Energy (DVN) Q2 2026 — Q2 2026 (ended June 30): total revenues $7,417M vs a $6,010M estimate - a $1,407M 'beat' that is $5,106M of wellhead oil, gas and NGL sales, $1,897M of zero-margin marketing pass-through and a $414M NON-CASH derivative mark. Wellhead sales alone were 15% BELOW the bar. Core EPS $1.57 vs $1.40 (+12.1%) is real; GAAP EPS $2.03. Oil 503 MBbl/d and 1,359 MBoe/d, both at the TOP of guidance; capital $1,269M, 2% under. The 8-K hit EDGAR at 4:11pm ET Tuesday, so Aug 5 is the reaction session: $44.05 to $42.09, DOWN 4.45%.

Devon's revenue beat is an accounting shape, not a business result. The 10-Q splits the $7,417M three ways: $5,106M of wellhead oil, gas and NGL sales (the actual business), $1,897M of marketing and midstream product bought and resold at a near-zero spread, and a $414M derivative GAIN inside the revenue caption. Wellhead sales alone came in 15% BELOW the $6,010M estimate - and the cash flow statement reverses that $414M as non-cash, then shows cash settlements on commodity derivatives of MINUS $116M. The EARNINGS beat is real: core EPS $1.57 vs $1.40.

THE CALL: BUY (3/5, A FORTRESS BALANCE SHEET AND A 12% FREE CASH FLOW YIELD, FOR ONE THIRD OF THE UPSIDE THE STREET SEES) — base-case value ~$49.0 vs ~$42.98 today.

KEY METRICS:

- CALL: BUY 3/5, fair value $49 vs the $42.98 Aug 7 close (+14.0%) plus a 3.0% dividend. Bull $61, bear $27, add under $40. Street: Buy, 64 analysts, 46 buy / 18 hold / 0 sell, avg target $61.15 (+42.3%) - which is our BULL case, to within a nickel.

- Revenue $7,417M vs a $6,010M bar, but wellhead sales were only $5,106M (15% UNDER) - $1,897M was marketing pass-through and $414M a non-cash derivative mark that cost $116M in CASH. Core EPS $1.57 vs $1.40 (+12.1%); GAAP $2.03.

- Oil 503 MBbl/d and 1,359 MBoe/d at the top of guidance; capital $1,269M (-2% vs midpoint); adjusted FCF $1.7B; net debt 0.73x EBITDAX; gas realised $1.05/Mcf.

What to watch: UP: core EPS $1.57 vs $1.40 (+12.1%); oil 503 MBbl/d and 1,359 MBoe/d at the TOP of guidance; capital 2% under midpoint; adjusted FCF $1.7B on a 44% reinvestment ratio; net debt ~0.73x EBITDAX, no maturities until Q2 2027; dividend +33% to $0.32; an $8.0B buyback to mid-2029 with shares already bought at $45.81 - above today's price; $1.0B of synergies targeted by year-end 2027, none of it in the numbers yet. DOWN: shares issued went 622M to 1,150M on the $24.9B all-stock Coterra merger; gas realised $1.05/Mcf on Waha basis while the merger doubled gas exposure; 207,500 Bbl/d of H2 oil (~37%) is capped at $72-$73 with Brent at $83.55; $2.6B went into 16,300 acres ($159,509/acre) that produce nothing until 2027; and a portfolio review is already underway.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Charles River Laboratories (CRL) Q2 2026 — Q2 2026 (quarter ended June 27, 2026): revenue $1,004.1M vs $1,032.1M, DOWN 2.7% reported but UP 0.1% organic - the first organic growth since Q3 2023, ending nine straight down quarters. Non-GAAP diluted EPS $3.02 vs a $2.77 bar (+9.0%), but DOWN 3.2% from $3.12. GAAP diluted EPS $(0.03) vs $1.06, on a $63.7M loss from the CDMO and Cell Solutions divestiture ($1.40/share). Non-GAAP operating margin 20.5% vs 22.1% (-160bp YoY) but up 420bp sequentially from 16.3%. Guidance RAISED: organic revenue 0.0% to +1.0% (was -1.5% to -0.5%), non-GAAP EPS $11.15-$11.45 (was $10.80-$11.30). The 8-K was accepted by the SEC at 7:15am ET (before the open), so Aug 5 is the reaction session: $234.12 to $260.72 (+11.36%), then $265.51 and $267.49 - up 14.25% over three sessions, to the highest close of the last twelve months.

The release states that the EPS decrease was 'partially offset by investment gains associated with the Company's deferred compensation plan, which totaled a net benefit of $0.19 per share in the second quarter.' That is a market mark on an executive compensation trust, and Charles River did NOT strip it out of the non-GAAP number the Street compares to. Take it out and run the buyback test: non-GAAP net income $146.2M less $0.19 x 48.421M shares is $137.0M; divided by LAST year's 49.316M diluted count, operations earned $2.78 against a $2.77 bar. A one cent beat. The buyback alone was worth $0.05 ($146.2M / 49.316M = $2.97 vs the reported $3.02), and $2.78 against $3.12 a year ago is DOWN 10.9%.

THE CALL: HOLD (4/5, THE BOOKINGS INFLECTION IS REAL AND THE TAPE HAS ALREADY PAID FOR IT TWICE) — base-case value ~$190.0 vs ~$267.49 today.

KEY METRICS:

- CALL: HOLD 4/5, fair value $190 vs the $267.49 Aug 7 close (-29.0%). Bull $235, bear $110, buy under $160. Street: Buy, 37 analysts, 27 buy / 10 hold / 0 sell, avg target $260.22 - already 2.7% BELOW the price.

- Revenue $1,004.1M -2.7% (organic +0.1%); non-GAAP EPS $3.02 +9.0% vs the bar but -3.2% YoY; GAAP EPS $(0.03). Operating margin 20.5% vs 22.1%.

- Strip the $0.19 deferred-comp mark and the $0.05 buyback and operations earned $2.78 against a $2.77 bar.

What to watch: UP: DSA net book-to-bill 1.19x, the highest since Q3 2022 and the THIRD straight quarter above 1.0x, on $701M of net bookings (+12.6% sequentially) and a $1.97B backlog; biopharma funding back near $100B; the K.F. Cambodia primate supplier turns into cheaper inventory in Q4; ~$70M of incremental annual savings; Investor Day on September 24, 2026. DOWN: revenue -2.7%, non-GAAP operating income -9.9%, H1 free cash flow $133.8M vs $281.7M (-52.5%), primate PRICING flat with any improvement landing in 2027, corporate overhead up 18.7% while revenue fell, net debt $2.43B vs $1.92B, and the raised guide requires H2 EPS of $6.23 vs $4.82 (+29.3%) with roughly half the margin gain from divestiture arithmetic. The CFO: 'Do not take the Q4 run rate and assume that that's the run rate going forward.'

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Keurig Dr Pepper (KDP) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): net sales $7,309M vs $4,163M, up 75.6% (constant currency +74.6%); excluding JDE Peet's, legacy KDP grew 7.3% on +4.2% price and +3.1% volume/mix. Adjusted diluted EPS $0.57 vs $0.49, +16.3%, against a Street bar near $0.537. But GAAP diluted EPS was $0.04, down 90.0%, and GAAP operating income FELL 30.1% to $628M while adjusted operating income rose 42.9% to $1,478M. Adjusted operating margin 20.2% vs 24.7%; adjusted gross margin 46.5% vs 55.0%. Full-year guidance reaffirmed. The 8-K was accepted by the SEC at 7:02am ET (before the open), so Aug 6 is a reaction session: $30.75 to $30.37 (-1.24%), then $30.01 (-1.19%) on Aug 7 - down 2.41% over two sessions and 14.7% below the 12-month closing high.

Net sales rose $3,146M year on year. Adjusted net income attributable to COMMON shareholders rose from $680M to $783M - $103M. That is 3.3 cents of adjusted earnings on each incremental revenue dollar, against a legacy business that converts 16.3 cents. The reconciliation is on the face of the release: JDE Peet's added $414M of adjusted segment operating income, adjusted interest expense rose $125M ($180M to $305M), tax at their own 23.1% adjusted rate takes it to ~$222M, then $82M was allocated to Preferred Investors and $68M to noncontrolling interests. About $72M a quarter reaches the common holder on $16,615M of cash deployed. And 53 of the 57 adjusted cents - 93% - are add-backs: $0.19 of deal/integration/financing cost, $0.17 of inventory step-up, $0.07 of intangible amortisation.

THE CALL: BUY (3/5, A GOOD BEVERAGE COMPANY AND A POOR COFFEE COMPANY, PRICED AS ONE MEDIOCRE ONE, EIGHTEEN MONTHS BEFORE THEY SEPARATE) — base-case value ~$34.0 vs ~$30.01 today.

KEY METRICS:

- CALL: BUY 3/5, fair value $34.00 vs the $30.01 Aug 7 close (+13.3%, +16.4% with the 3.07% dividend). Bull $46, bear $20, add under $27. Street: Buy, 28 analysts, 16 buy / 12 hold / 0 sell, avg target $35.67.

- Net sales $7,309M +75.6%; adjusted EPS $0.57 +16.3%; GAAP EPS $0.04 -90.0%. Adjusted operating margin 20.2% vs 24.7%.

- $3,146M of new revenue produced $103M of new adjusted earnings to common - 3.3 cents on the dollar.

What to watch: UP: the separation into Beverage Co. and Global Coffee Co. is targeted for EARLY 2027 and forces the market to price a 29.9%-margin U.S. Refreshment Beverages business (volume/mix +6.5%, price +3.5%) separately from a mediocre coffee business; the ~$400M of announced cost synergies showing up in segment margins; green coffee cost normalising so U.S. Coffee stops losing margin; deleveraging toward the 4.1x year-end target. DOWN: the separation date slipping out of early 2027 (our model discounts a 2027 sum-of-the-parts back to today); U.S. Coffee adjusted operating income staying down double digits after -24.7% this quarter despite +5.0% price; the year-end leverage ratio missing 4.1x; and the quiet one - structured payables went from $25M at Dec 31 to $1,018M at Jun 30, and if that supply-chain financing reverses it comes straight out of operating cash flow.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Roivant Sciences (ROIV) Q1 FY2026 — Q1 FY2026 (quarter ended June 30, 2026): net loss per share $(0.26) vs $(0.33), a 21% improvement. Revenue was $1.4M - not billion, million; nothing in the portfolio is approved anywhere. Cash and securities $3.9B against $385M of total liabilities and zero debt. But the company's own adjusted net loss was $243.7M vs $170.1M (43% WORSE) and cash used in operations was $270.5M vs $204.4M (32% worse). Total consolidated net loss WIDENED 6% to $290.6M. The 8-K was accepted by the SEC at 7:13am ET (before the open), so Aug 6 is the reaction session: +1.5% to $35.12, then +3.47% to $36.34 - up 5.03% over two sessions, 1% below the 12-month closing high.

Roivant's headline improvement is ownership arithmetic, not operations. Total consolidated net loss got 6% BIGGER ($273.9M to $290.6M) - the reported improvement comes from the loss pushed onto Immunovant's minority holders DOUBLING, from $50.6M to $100.8M. Divide the $189.8M attributable loss by LAST year's 680.3M share count and you get $(0.28), not the printed $(0.26): 2 of the 7 cents of improvement is just a bigger denominator. Despite $208.7M of buybacks, shares outstanding still ROSE 5.9%, because $83M of quarterly share-based comp outran the repurchase.

THE CALL: SELL (3/5, AN EXCEPTIONAL BALANCE SHEET AND A STRONG PIPELINE, AT A PRICE THAT ALREADY ASSUMES ALL OF IT WORKS) — base-case value ~$20.0 vs ~$36.34 today.

KEY METRICS:

- CALL: SELL 3/5, fair value $20.00 vs the $36.34 Aug 7 close (-45%). Bull $28, bear $12, buy under $17. Street: Buy, 15 analysts, 14 buy / 1 hold / 0 sell, avg target $38.33.

- EPS $(0.26) vs $(0.33) (-21%), BUT adjusted net loss $243.7M +43% and cash burn $270.5M +32%. Total consolidated net loss $290.6M, +6%.

- Observable value is $11.59/sh ($3.26B net liquid + 52% of Immunovant + marks). So $24.75/sh - 68% of the price - is unapproved pipeline.

What to watch: UP: brepocitinib (oral JAK1/TYK2) is under FDA review in dermatomyositis with a decision guided to Q3 CY2026 and launch targeted by end-September; a positive Phase 3 in non-infectious uveitis in 2H; the cutaneous sarcoidosis Phase 3 (Phase 2 showed 77% of treated patients hitting the endpoint vs 0% on placebo, Breakthrough Therapy Designation, no approved therapy) reading out; Pulmovant's mosliciguat in pulmonary hypertension in 2H; Immunovant's anti-FcRn programme re-rating the 55% stake. Any of those lifts our risk-adjusted peak and the $28 bull case becomes the base. DOWN: quarterly burn goes through $350M while the buyback continues and the 16-quarter runway compresses; one readout misses and the Immunovant mark - itself at a 12-month high on a 38% float - goes with it.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Iron Mountain (IRM) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $2,029.1M vs $1,711.9M, +18.5% reported, +17.6% constant-currency and +16.8% organic. Storage rental $1,134.6M +12.3%; service $894.5M +27.4%. Net income $106.1M vs a $(43.3)M loss. Adjusted EPS $0.60 vs a $0.56 bar (+7.1% beat). Adjusted EBITDA $727.0M +15.7%, but margin fell 90bp to 35.8%. AFFO $432.7M +17.0%, $1.44/share +16.1%. FY2026 guidance raised on all four lines: revenue $7,940-8,010M, adjusted EBITDA $2,945-2,975M, AFFO $1,760-1,780M, AFFO/share $5.87-5.93. The 8-K was accepted at 6:47am ET (before the open), so Aug 5 is the reaction session: +1.29% to $127.13, then -4.07% and -0.66% to $121.15 - the move fully reversed.

Iron Mountain printed a record quarter, beat on adjusted EPS and raised full-year guidance on every line - and the stock is down 4.7% since the close of the day it reported. The segment tables explain why. Organic physical storage volume grew 0.6%, so roughly 90% of the legacy engine's growth is price rises off a flat base. The single biggest contributor to revenue growth, Corporate and Other, added $134M and still printed NEGATIVE adjusted EBITDA. And AFFO per share has printed $1.44, $1.43 and $1.44 for three straight quarters. We also tested and KILLED the dilution story: diluted shares rose just 0.74%.

THE CALL: SELL (3/5, A GOOD BUSINESS AT A MULTIPLE THAT ONLY THIRTEEN PERCENT OF IT DESERVES) — base-case value ~$100.0 vs ~$121.15 today.

KEY METRICS:

- CALL: SELL 3/5, fair value $100 vs the $121.15 Aug 7 close (-17.5%). Bull $130, bear $69. Street: Buy, 20 analysts, avg target $138.25.

- Revenue $2,029M +18.5% (+16.8% organic); AFFO $433M / $1.44 +17%. But adjusted EBITDA margin FELL 90bp to 35.8%.

- Organic storage VOLUME +0.6% - ~90% of legacy growth is price. Corporate & Other added $134M of revenue with NEGATIVE EBITDA.

What to watch: UP: the 75MW signed in July converts into commenced, revenue-producing capacity at the yields renewals imply (cash mark-to-market +11.8%), which would re-rate the data centre platform above 22x and make our $130 bull case the base; the 684MW land bank and the 160MW under construction (71.2% pre-leased) fund out; Corporate and Other (ALM + digital) crosses into positive adjusted EBITDA and stays there; organic storage VOLUME finally inflects above ~1%. DOWN: Q3 AFFO/share lands at or below the guided ~$1.47, making the implied ~$1.56 Q4 (an 8% sequential jump) unreachable; storage pricing hits its ceiling as customers scan archives; the BB-/Ba3 credit outlook changes while the company still needs ~$1.5B a year of external funding for growth capex.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Becton Dickinson (BDX) Q3 FY2026 — Q3 FY2026 (quarter ended June 30, 2026): revenue $4,983M vs $4,726M, +5.4% reported and +4.4% currency-neutral, against a $4,887M bar - a 2.0% beat. GAAP diluted EPS from continuing operations $1.64 vs $1.57 (+4.5%); adjusted diluted EPS $3.23 vs $3.08 (+4.9%), against a $3.14 bar - a nine-cent BEAT. Total GAAP EPS including discontinued operations $1.37. FY2026 adjusted EPS guidance raised at the midpoint to $12.62-$12.72 from $12.52-$12.72. The 8-K was accepted at 6:31 a.m. ET Thursday Aug 6, so Thursday WAS the reaction: +3.76% to $177.07 from $170.66. Friday Aug 7 closed $176.86, -0.12% - the move held.

A wall of coverage called BD's fiscal Q3 a miss, comparing GAAP EPS of $1.64 against a stale pre-separation estimate above $2. It was not a miss - FMP's own tracked actual is the adjusted $3.23 against a $3.14 bar. But the usual explanation is wrong too: 83% of the $1.59 GAAP-to-adjusted gap is purchase-accounting amortisation ($1.32/share, and it was $1.31 a year ago), not separation noise. Only $0.12 is separation cost. And the beat is not a beat either: GAAP net income from continuing operations was $451M in both years, to the dollar, and adjusted net income rose $4.2M. Our fair value is $176 against the $176.86 close.

THE CALL: HOLD (3/5, A FAIRLY PRICED BUSINESS WITH NO MARGIN OF SAFETY, WHERE THE EARNINGS DOLLARS HAVE NOT ACTUALLY GROWN) — base-case value ~$176.0 vs ~$176.86 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value $176 vs the $176.86 Aug 7 close (-0.5%). Bull $249, bear $111. Street: Hold, 34 analysts, avg target $185.63.

- Revenue $4,983M +5.4%; adjusted EPS $3.23 vs a $3.14 bar. But GAAP net income from continuing ops was $451M in BOTH years - flat to the dollar.

- 90% of the 15c adjusted EPS gain is the buyback: shares -4.2%. On last year's share count the quarter earned $3.09 - below the $3.14 bar.

What to watch: UP: adjusted operating margin finally guided higher as Excellence Unleashed removes stranded costs (GAAP operating margin fell 234bp to 13.3% this quarter); Medication Delivery (+1.6% FXN) and Medication Management (+2.3% FXN) inflecting - together almost half the company; owner earnings reaching $2.85B, which returns $249 in our model; further debt paydown lowering the discount rate. DOWN: the working-capital swing reversing (it was 107% of the nine-month operating cash flow increase); tariffs, which BD bases guidance on as of Aug 5 with certain refunds unresolved; the buyback ending when the $3.86B Waters distribution is spent, leaving EPS to grow the hard way.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Royal Gold (RGLD) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $450.5M vs $209.6M, up 114.9%, but 1.8% BELOW the $458.85M Street bar. GAAP EPS $2.78 vs $2.01; adjusted EPS $2.56 vs $1.81, against a $2.55 bar - a one-cent beat. GEOs sold 100,000 vs 63,900 (+56.5%). Record operating cash flow $335.2M. The 8-K was accepted at 5:14 p.m. ET Wednesday Aug 5, so Thursday Aug 6 was the reaction: +1.40% to $218.11 on 801,643 shares against a 709,878 three-month average - LESS volume than the day before the print. Friday Aug 7 rose 5.41% to $229.92 on a ~2% move in spot gold.

Royal Gold grew revenue 114.9% and printed record operating cash flow of $335.2 million - and the stock moved 1.4%, on LESS volume than the day before the print. The reason is a second 8-K, filed July 21, that published almost the entire operating quarter fifteen days early: stream sales of $311.0M, 69,000 stream GEOs, cost of sales of $871/GEO, a royalty range of $137-142M and a DD&A range of $95-99M. Royalty revenue landed at $139.6M - the guided midpoint. Our fair value is $212 against the $229.92 close.

THE CALL: HOLD (3/5, AN EXCELLENT BUSINESS AT A PRICE THAT ALREADY ASSUMES GOLD RETURNS TO ITS FIRST-QUARTER PEAK AND STAYS THERE) — base-case value ~$212.0 vs ~$229.92 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value $212 vs the $229.92 Aug 7 close (-8.5%). Bull $259, base $208, bear $192. Street: Buy, 28 analysts, avg target $301.50.

- Revenue $450.5M +114.9%; adjusted EPS $2.56 vs a $2.55 bar. But the whole operating quarter was pre-announced July 21, and revenue MISSED by 1.8%.

- GEOs per share +21%, not +56.5%: shares +29.1% for Sandstorm. Depletion per GEO $962 vs $488. Realised gold $4,873 Q1, $4,506 Q2, spot ~$4,357.

What to watch: UP: gold sustaining above $5,000/oz (our model returns $236 at $5,000 and $259 at $5,500); the 145,000 oz of silver and 1,300 oz of gold left in inventory converting in Q3 (~16c/share); Hod Maden, Warintza and Cascabel starting to contribute ounces; the second $50M Solaris payment perfecting. DOWN: the realised gold price series continuing to fall ($4,873 in Q1, $4,506 in Q2, ~$4,357 spot); depletion per GEO staying near $962; copper/other metals rolling over after running above the top of guidance.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Zoetis (ZTS) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $2.468B vs $2.474B, flat reported and -1% organic operational, against a ~$2.50B Street bar (a 1.3% MISS). GAAP EPS $1.65 vs $1.63; adjusted EPS $1.87 vs $1.78, against a $1.85 bar. But adjusted NET INCOME fell 1%, from $791M to $781M - diluted shares went 445.5M to 417.7M. Companion Animal revenue -$82M; Livestock +$80M; total -$6M. Dermatology $398M vs $473M (-15.9%). U.S. companion animal -11% for a second straight quarter. FY2026 guidance CUT: revenue $9.120-$9.320B (was $9.680-$9.960B), adjusted EPS $6.15-$6.25 (was $6.85-$7.00), organic operational revenue growth (3)% to (1)% (was +2% to +5%). The 8-K was accepted 7:06 a.m. ET Thursday Aug 6 (before the open); the stock closed Thursday at $77.27, +3.87%, then Friday at $72.66, -5.97%.

Zoetis beat by two cents - $1.87 adjusted against a $1.85 bar - and the stock gapped up six percent and closed Thursday up 3.87% at $77.27. Friday it closed at $72.66, down 5.97%, BELOW the $74.39 it traded at before the print. The beat lasted exactly one session. Here is what the tape worked out overnight. FIRST: adjusted net income FELL 1% (from $791M to $781M) while adjusted EPS ROSE 5% - both sentences are in the same bullet of the same release. The entire gap is 27.8 million retired shares. Divide $781M by LAST year's 445.5M diluted shares and the quarter earns $1.753 - down 1.3% year over year, and a 9.5-cent MISS against the $1.85 bar. The buyback is 124% of the EPS growth. SECOND: full-year guidance was cut on the same morning - adjusted EPS from $6.85-$7.00 to $6.15-$6.25, a 10.5% cut, and 12.1% below the $7.00-$7.10 set in February. Subtract the $3.40 already banked in H1 and the new midpoint implies an H2 of $2.80 against $3.22 last year - DOWN 13%. THIRD: 'Revenue flat at $2.5 billion' is an accident. Companion Animal fell $82M and Livestock rose $80M, and the release attributes the livestock strength to poultry vaccine sales 'tied to disease outbreak activity' plus New World screwworm. Meanwhile dermatology - Apoquel and Cytopoint - fell 15.9%.

THE CALL: HOLD (3/5, MOST OF THE BAD NEWS IS IN THE PRICE, BUT THE COMPANY'S OWN GUIDANCE SAYS THE TROUGH IS STILL AHEAD) — base-case value ~$77.0 vs ~$72.66 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value $77 vs the $72.66 Aug 7 close (+6%). Bull $106, base $80, bear $55. Street: Hold, 31 analysts, avg target $99.17.

- Revenue $2.468B, flat, a 1.3% miss. Adjusted EPS $1.87 vs $1.85 - but adjusted net income FELL 1%. On last year's shares: $1.75, a 9.5c MISS.

- FY26 adjusted EPS guidance cut 10.5% to $6.15-$6.25; implied H2 $2.80 vs $3.22. Dermatology -15.9%. 11.7x EPS, 9.5x EBITDA, 7.0% FCF yield.

What to watch: UP: U.S. companion animal improving off -11% (it has printed -11% twice running); dermatology stabilising off -15.9%; Lenivia and Portela scaling the OA-pain franchise; the Neogen animal-genomics deal closing and contributing; a price under $62. DOWN: Q3 in early November failing the implied $2.80 second half; livestock giving back the outbreak-driven +23% as poultry and screwworm comparisons normalise; the International Fiscal Year Alignment pull-forward (~$100M in Q1 alone) reversing; the last $1.3B of buyback authorisation running out; escalation in the S.D.N.Y. securities class action over Librela, Simparica Trio, Apoquel and Cytopoint.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Republic Services (RSG) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $4.430B vs $4.235B, +4.6%, against a ~$4.41B Street bar. GAAP EPS $1.84 vs $1.75; adjusted EPS $1.85 vs $1.77, against a $1.81-$1.83 bar. Adjusted EBITDA $1.423B, margin 32.1%, flat YoY. Operating income $901M, +4.6%. But income before income taxes was $699M vs $720M, DOWN 2.9%, with the effective tax rate falling 23.6% to 19.0%. Diluted shares 307.6M vs 313.4M. H1 adjusted FCF $1.583B vs $1.420B; H1 cash taxes paid $79M vs $150M. FY2026 guidance: revenue $17.200-$17.300B, adjusted EBITDA $5.525-$5.550B, adjusted EPS $7.23-$7.28, adjusted FCF $2.540-$2.575B. Dividend raised ~7% to $0.670/qtr. The 8-K was accepted 4:08 p.m. ET Thursday Aug 6 (after the close); the stock closed Friday Aug 7 at $214.56 vs $209.59, up 2.37%.

Republic Services beat by two to four cents - $1.85 adjusted against a $1.81-$1.83 bar - grew revenue 4.6% to $4.430B, raised full-year guidance, and the stock added 2.37%. The business is genuinely excellent and we say so. Our objection is what the raise decodes to. Republic raised revenue guidance 0.9%, adjusted EBITDA 0.7% and free cash flow 0.7% - and adjusted EPS by 0.2%, with the TOP of the range ($7.28) not moving at all since February. Three lines of the release say 'Increased original guidance'; the EPS line says 'Updated'. Subtract the $3.55 already banked in H1 and the new $7.23-$7.28 implies a second half of $3.68-$3.73 against $3.66 last year - growth of 0.5% to 1.9%, midpoint 1.2%, against +5.7% delivered in H1 and +7.6% in Q1. Separately, pre-tax income FELL 2.9%. We tested the obvious 'tax-rate rescue' explanation and it is FALSE: the Section 48 tax credits are offset by matching equity-method JV losses, a net $12M drag. But cash taxes paid fell from $150M to $79M, and that $71M is 44% of the entire $163M increase in adjusted free cash flow.

THE CALL: HOLD (3/5, AN EXCELLENT BUSINESS, A SMALL BEAT, A GUIDANCE RAISE THAT DECODES TO 1.2% SECOND-HALF GROWTH, AND A PRICE OFFERING 7.2% A YEAR) — base-case value ~$184.0 vs ~$214.56 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value $184 vs the $214.56 Aug 7 close (-14%). Bull $226, base $181, bear $155. Street: Buy, 35 analysts, avg target $237.

- Revenue $4.430B, +4.6%. Adjusted EPS $1.85 vs a $1.81-$1.83 bar. Adj EBITDA $1.423B at a flat 32.1% margin. But pre-tax income FELL 2.9% to $699M.

- EPS guidance midpoint rose 0.2% and implies +1.2% H2 growth. H1 cash taxes $79M vs $150M = 44% of the FCF increase. 29.6x EPS, 25.8x FCF.

What to watch: UP: core price on related business re-accelerating back above 7% (it decelerated 7.0% to 6.4%); volume turning positive from -1.9%; Environmental Solutions recovering the 420bp of margin it lost (24.4% to 20.2%); a price in the $160s. DOWN: Q3 in late October failing the implied 1.2% H2 growth; cash taxes converging on the book rate as the renewable credit pipeline matures; recycled commodity prices below $136/ton; core price under 6%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Halozyme Therapeutics (HALO) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): total revenue $481.0M vs $325.7M, +47.7%, against a ~$402M Street bar. Royalties $307.7M, +49.6%; product sales $129.6M, +59.0%. GAAP EPS $1.90 vs $1.33; non-GAAP net income $272.6M / $2.28 diluted EPS vs $191.3M / $1.54, against a $1.79 bar. Adjusted EBITDA $328.8M vs $225.5M, +45.8%, a 68.4% margin. Non-GAAP diluted shares 119.7M vs 124.0M. FY2026 guidance RAISED on all four lines: revenue $1.835-$1.910B, royalties $1.220-$1.245B, adjusted EBITDA $1.225-$1.280B, non-GAAP EPS $8.65-$9.00. The 8-K was accepted 4:08 p.m. ET Thursday Aug 6 (after the close); the stock closed Friday Aug 7 at $103.12 vs $85.76, up 20.24%, an all-time high.

Halozyme beat by 27% - $2.28 non-GAAP against a $1.79 bar - grew revenue 47.7% to $481.0M, raised guidance on all four lines, and the stock added 20.24% to the highest close in its history. The quarter is outstanding and we say so. Our objection is two numbers printed beside it. FIRST: the guidance growth rates are measured against a broken base. Halozyme's own February release says adjusted EBITDA of $657.6M 'included acquired IPR&D expense of $284.9 million related to the Surf Bio acquisition', and that non-GAAP EPS of $4.15 'included an unfavorable impact of approximately $2.30 per share' from it. Clean, FY2025 was $942.5M of EBITDA and about $6.45 of EPS - so the guided '86% to 95%' is really 30-36% and the guided '108% to 117%' is really 34-40%, roughly a third of what was quoted. SECOND: the 10-K says the U.S. rHuPH20 patent behind the royalty rate 'expires in 2027', Europe in 2029, and the 10-Q says the rate is REDUCED - not terminated - with the size of that step-down undisclosed. Two tests both came back FALSE: the bar was never walked down, and the beat was not bought ($272.6M on last year's 124.0M shares is still $2.20, so 89% of the EPS growth is operating).

THE CALL: AVOID (3/5, AN OUTSTANDING QUARTER, A GUIDANCE HEADLINE THAT FLATTERS IT, AND A PRICE THAT ALREADY PAYS FOR THE BULL CASE) — base-case value ~$82.0 vs ~$103.12 today.

KEY METRICS:

- CALL: AVOID 3/5, fair value ~$82 vs the $103.12 Aug 7 close (-20%). Bull $126, base $81, bear $48. Street: Buy, 27 analysts, avg $99 - itself BELOW the tape.

- Revenue $481.0M, +47.7%; royalties $307.7M, +49.6%. Non-GAAP EPS $2.28 vs a $1.79 bar. Adj EBITDA $328.8M, +45.8%, a 68.4% margin. H1 free cash flow $413.1M.

- FY2025 adj EBITDA of $657.6M included a $284.9M Surf Bio IPR&D charge. Clean base $942.5M, so the guided +86-95% is really +30-36%. US ENHANZE patent expires 2027.

What to watch: UP: a disclosure quantifying the post-2027 royalty step-down as smaller than feared; a Q3 delivering the implied 24% H2 ramp ($694M vs $558M); more Hypercon deals with mid-2040s patent lives. DOWN: royalty growth below 30%; H2 missing the implied $694M; concentration above 69% of receivables; partners reformulating around the enzyme ahead of 2027.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.